Brett Andrew King
MD, PhD
Medicine
Dermatology
Middlebury, Connecticut, United States
Associate Professor
Brett King, MD, Ph.D., is an Associate Professor of Dermatology, specializing in skin diseases recalcitrant to first-line therapies. He has pioneered the use of Janus kinase (JAK) inhibitors in cutaneous diseases, in particular for alopecia areata, vitiligo, atopic dermatitis, granuloma annulare, sarcoidosis, and erosive lichen planus, in addition to other disorders. He sees patients at Yale Dermatology-Middlebury.
He is experienced with the use of systemic medications including retinoids, methotrexate, cyclosporine, azathioprine (Imuran), mycophenolate mofetil (Cellcept), tofacitinib (Xeljanz), baricitinib (Olumiant), upadacitinib (Rinvoq), ruxolitinib (Jakafi), apremilast (Otezla), and the ‘biologics’ (e.g. etanercept (Enbrel), adalimumab (Humira), infliximab (Remicade), ustekinumab (Stelara), sekucinumab (Cosentyx), ixekizumab (Taltz), IVIG, and rituximab (Rituxan)), as well as phototherapy.
Dr. King received his B.A. at the University of California at Santa Cruz, his Ph.D. from Stanford University, and his M.D. from Yale University School of Medicine. He completed a medical internship at Massachusetts General Hospital and a dermatology residency at Yale University School of Medicine.
